THE IMI T2EVOLVE Project and the Horizon 2020 QUALITOP Project have launched a European patient survey on CAR-T treatment. The survey aims to inform on patient and carer experiences and challenges of receiving CAR-T and to identify information needs and gaps across Europe. The results of the survey will be used for research purposes and published anonymously on project partner websites as well as in academic journals.
The T2EVOLVE-QUALITOP European patient survey on CAR-T treatment is searching for European patients older than 18 years old who received this therapy for any haematologic malignancy to participate in it. The survey is available in English, French, German, Spanish, Italian, Portuguese, and Dutch.
T2EVOLVE is a project executed by an alliance of academic and industry leaders in cancer immunotherapy. The project is funded by the European Union’s Innovative Medicines Initiative (IMI). QUALITOP stands for “monitoring multidimensional aspects of QUAlity of Life after cancer ImmunoTherapy – an Open smart digital Platform for personalised prevention and patient management.” The project is funded by the European Union’s Horizon 2020 research and innovation programme.
Click here to learn more about MPE research projects.